The estimated Net Worth of Patricia S Andrews is at least $224 Tausend dollars as of 16 November 2021. Ms. Andrews owns over 40,000 units of GlycoMimetics Inc stock worth over $7,240 and over the last 16 years she sold GLYC stock worth over $0. In addition, she makes $217,210 as Independent Director at GlycoMimetics Inc.
Sign up
Ms. Andrews GLYC stock SEC Form 4 insiders trading
Patricia has made over 1 trades of the GlycoMimetics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 40,000 units of GLYC stock worth $82,000 on 16 November 2021.
The largest trade she's ever made was buying 40,000 units of GlycoMimetics Inc stock on 16 November 2021 worth over $82,000. On average, Patricia trades about 2,222 units every 0 days since 2008. As of 16 November 2021 she still owns at least 45,250 units of GlycoMimetics Inc stock.
You can see the complete history of Ms. Andrews stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Patricia Andrews biography
Patricia S. Andrews serves as Independent Director of the Company. Ms. Andrews has served as a member of our Board since June 2017. She has served as Chief Executive Officer of Boston Biomedical, Inc., an oncology drug research and development company, and as an executive officer of its parent company, Sumitomo Dainippon Pharma Co. Ltd., since April 2017. Ms. Andrews joined Boston Biomedical in November 2013 and previously served as its Chief Operating Officer. From October 2008 to August 2012, Ms. Andrews served as Chief Commercial Officer of Incyte Corporation, a publicly held biopharmaceutical company. From 1991 to 2008, Ms. Andrews served in various roles of increasing responsibility at Pfizer Inc., culminating in her role as Vice President and General Manager of Pfizer’s U.S. Oncology business unit. Ms. Andrews received her B.A. degree from Brown University and her M.B.A. degree from the University of Michigan.
What is the salary of Patricia Andrews?
As the Independent Director of GlycoMimetics Inc, the total compensation of Patricia Andrews at GlycoMimetics Inc is $217,210. There are 10 executives at GlycoMimetics Inc getting paid more, with Rachel King having the highest compensation of $2,689,070.
How old is Patricia Andrews?
Patricia Andrews is 62, she's been the Independent Director of GlycoMimetics Inc since 2017. There are 5 older and 11 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
What's Patricia Andrews's mailing address?
Patricia's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at GlycoMimetics Inc
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris und M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
What does GlycoMimetics Inc do?
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
What does GlycoMimetics Inc's logo look like?
Complete history of Ms. Andrews stock trades at GlycoMimetics Inc und Incyte
GlycoMimetics Inc executives and stock owners
GlycoMimetics Inc executives and other stock owners filed with the SEC include:
-
Rachel King,
President, Chief Executive Officer, Co-Founder, Director -
Brian Hahn,
Chief Financial Officer -
Helen Thackray,
Senior Vice President - Clinical Development, Chief Medical Officer -
John Magnani,
Co-Founder, Senior Vice President, Chief Scientific Officer -
Rachel K. King,
Pres, CEO & Director -
Brian M. Hahn,
Sr. VP & CFO -
Timothy Pearson,
Independent Chairman of the Board -
Daniel Junius,
Independent Director -
Mark Goldberg,
Independent Director -
Scott Jackson,
Independent Director -
Patricia Andrews,
Independent Director -
Scott Koenig,
Independent Director -
Armand Girard,
Senior Vice President, Chief Business Officer -
Bruce Johnson,
Sr. VP & Chief Commercial Officer -
Armand Girard,
Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. -
Dr. John L. Magnani,
Sr. VP of Research & Chief Scientific Officer -
Harout Semerjian,
CEO, Pres & Director -
Dr. Eric J. Feldman M.D.,
Sr. VP & Chief Medical Officer -
Christian Dinneen-Long,
VP, Corp. Counsel & Corp. Sec. -
Henry Flanner,
VP of Technical Operations -
Stephanie R. Irish,
VP of Accounting -
Partners L P/Ilbiotechnolog...,
-
Scott D Sandell,
10% owner -
Franklin H Jr Top,
Director -
Peter J Barris,
10% owner -
Michael A Henos,
Director -
M James Barrett,
Director -
Enterprise Associates 10 L ...,
-
John J. Baldwin,
Director -
Chinmaya Rath,
SVP and Chief Business Officer -
William M. Gust,
Director -
Enterprise Associates 13 Lp...,
-
Partners L P/Ilbiotechnolog...,
-
Harout Semerjian,
Chief Executive Officer -
Public Equities, L.P.Artal ...,
-
Public Equities, L.P.Invus ...,
-
Bruce S Johnson,
SVP & Chief Commercial Officer -
Edwin Rock,
Chief Medical Officer